Citation APA
Devos, T., Geukens, T., Schauvlieghe, A., Ariën, K. K., Barbezange, C., Cleeren, M., Compernolle, V., Dauby, N., Desmecht, D., Grimaldi, D., Lambrecht, B., Luyten, A., Maes, P., Moutschen, M., Romano, M., Seyler, L., Toungouz Nevessignsky, M., Vandenberghe, K., Van Griensven, J., Verbeke, G., Vlieghe, E., Yombi, J.-C., Liesenborghs, L., Verhamme, P., & Meyfroidt, G. (2020). A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial. Trials, 21(1). doi:10.1186/s13063-020-04876-0
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/314758